All In Biotech

Drug Trial Radar · NCT06173037

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

A Multicenter, Single-arm, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC88 Monotherapy in Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jan 19, 2024

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RC88 monotherapy in subjects with Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Conditions

  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer
  • Epithelial Ovarian Cancer

Interventions

  • RC88Drug

    2.0 mg/kg Q3W IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Up to approximately 2 years

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Xingtai People's Hospital

    Xingtai, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Shandong Cancer Hospital, Shandong Cancer Institute

    Jinan, Shandong, China

  • Qingdao Central Hospital

    Qingdao, Shandong, China

  • Qilu Hospital of Shandong University

    Jinan, Shangdong, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • The West China Second University Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.